30 research outputs found
A Compact Beam Stop for a Rare Kaon Decay Experiment
We describe the development and testing of a novel beam stop for use in a
rare kaon decay experiment at the Brookhaven AGS. The beam stop is located
inside a dipole spectrometer magnet in close proximity to straw drift chambers
and intercepts a high-intensity neutral hadron beam. The design process,
involving both Monte Carlo simulations and beam tests of alternative beam-stop
shielding arrangements, had the goal of minimizing the leakage of particles
from the beam stop and the resulting hit rates in detectors, while preserving
maximum acceptance for events of interest. The beam tests consisted of
measurements of rates in drift chambers, scintilation counter hodoscopes, a gas
threshold Cherenkov counter, and a lead glass array. Measurements were also
made with a set of specialized detectors which were sensitive to low-energy
neutrons, photons, and charged particles. Comparisons are made between these
measurements and a detailed Monte Carlo simulation.Comment: 39 pages, 14 figures, submitted to Nuclear Instruments and Method
Genetic variability among sorghum accessions for seed starch and stalk total sugar content
Steroid-sparing agents in giant cell arteritis
Background:
Giant cell arteritis is the commonest form of medium-to-large vessel vasculitis, requiring long-term corticosteroid therapy. The short- and long-term side effects of corticosteroids are many, including weight gain, psychological effects, osteoporosis, cardiometabolic complications, and infections.
Materials and Methods:
Various agents used in place of or in combination with corticosteroids to reduce corticosteroid-related side effects were reviewed. However, considerable variation in practice was identified giving unclear guidance. This review included the most recent evidence on methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, abatacept, and tocilizumab
Results and Discussion:
Also discussed are encouraging results with tocilizumab in GCA patients. Amongst the agents available for steroid-sparing effects, tocilizumab demonstrated the most robust data and is consequently recommended as the agent of choice for steroid-sparing, for remission induction, remission maintenance, and treating relapsing and refractory cases of GCA.Published versio
New insights into the genetic etiology of Alzheimer's disease and related dementias
Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele